Tirzepatide : Treatment For Diabetes Mellitus II & Obesity
Abstract
Keywords
Full Text:
PDFReferences
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, Joanna Bojarska and Vasso Apostolopoulos ; Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Bokvist BK, Coskun T, Cummins RC, Alsina- Fernandez J, "GIP and GLP-1 co-agonist compounds",US patent 9474780, issued 2016-10-25, assigned to Eli Lilly and Co
Sagonowsky, Eric (26 October 2021). "As Lilly gears up for key 2022 launches, Trulicity,Taltz and more drive solid growth". Fierce Pharma. Archived from the original on 14 May 2022. Retrieved 9 April 2022.
Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the original on 29 April 2022.Retrieved 29 April 2022.
Francis S Willard, et al. JCI Insight. 2020 Sep 3;5(17):e140532. [6] Coskun T, et al. Mol Metab. 2018 Dec;18:3-14.
Bucheit J, Ayers J, Pamulapati L, Browning A, Sisson E. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J Cardiovasc Pharmacol. 2022 Aug 01;80(2):171-179.
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3.
Frias JP: Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
Min T, Bain SC: The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15.
Straight Healthcare
Frederick, M.O.; Boyse, R.A.; Braden, T.M.; Calvin, J.R.; Campbell, B.M.; Changi, S.M.; Coffin, S.R.; Condon, C.; Gowran,O.; McClary, J.; et al. Kilogram-scale GMP manufacture of tirzepatide using a hybrid SPPS/LPPS approach with continuous manufacturing. Org. Process Res. Dev. 2021, 25, 1628–1636.
May, S.A.; Johnson, M.D.; Buser, J.Y.; Campbell, A.N.; Frank, S.A.; Haeberle, B.D.; Hoffman, P.C.; Lambertus, G.R.; McFarland,A.D.; Moher, E.D.; et al. Development and manufacturing GMP scale-up of a continuous ir-catalyzed homogeneous reductiveamination reaction. Org. Process Res. Dev. 2016, 20, 1870–1898.
Wang, Z.; Wang, Z.; Lin, S.; Jin, H.; Gao, S.; Zhu, Y.; Jin, J. Nanoparticle-templated nanofiltration membranes for ultrahigh performance desalination. Nat. Commun. 2018, 9, 2004–2013.
FDA Approved Drug Products: MOUNJARO (tirzepatide) Injection, for subcutaneous use
Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-107. [PubMed]
Farzam K, Jan A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 27, 2022. Beta Blockers. [PubMed]
Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. [PMC free article] [PubMed]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]
Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021 Jan;44(1):290-296. [PMC free article] [PubMed]
Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 05;27(13) [PMC free article] [PubMed]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K., SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 05;385(6):503-515. [PubMed]
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157.
Kroopnick JM, Davis SN. The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. Expert Opin Pharmacother. 2022 Aug;23(11):1259-1271. [PubMed] [26] Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. (PubMed ID 30473097)
www.drugbank.com
Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]. [29]https://naomedical.com/health/tirzepatide-overdose-symptoms-treatment-prevention/?amp=1
Jastreboff A.M., Aronne L.J., Ahmad N.N., Wharton S., Connery L., Alves B., Kiyosue A., Zhang S., Liu B., Bunck M.C., et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 2022;11:127. doi: 10.1056/NEJMoa2206038. [PubMed] [CrossRef] [Google Scholar]
DOI: https://doi.org/10.37591/rrjodfdp.v10i2.1339
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production